Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...
Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. After brushing off a recommendation to end a phase 3 study earlier this year based on ...
Symptoms of Parkinson’s disease, which afflicts around 1 million Americans, usually begin gradually and worsen over time.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback